drugset
drugset / Trial / NCT05905497

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497 ↗

Phase 1 Completed 14 enrolled Atea Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects

Timeline

Start
2023-04-26
Primary completion
2023-05-19
Completion
2023-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — Oral

Indications

No indication recorded.